Biopharma’s “patent cliff” isn’t just a legal event—it’s a commercial deadline.
If you’re a biopharma commercial, market access, or business development vendor, the window to win EU tenders before patent expiry is where deals are made—or lost. And in…

Biopharma’s next talent magnet isn’t a lab—it’s a courtroom.
If you want to understand where the industry is headed, don’t just watch the next clinical readout. Watch the patent wars.
A new analysis from DrugPatentWatch on biosimilar patent litigatio…

Specialty pharmacy contracts don’t get “won” after a patent cliff—they get won before the cliff is even visible on the balance sheet.
In biopharma, the commercial market-access window is often treated like a downstream problem: secure coverage, negotia…

Pharmacology Keeps Sighing: Can This Drug Do That? The Internet Keeps Asking.
Every few days, the same question resurfaces—usually in a thread that starts with genuine curiosity and ends with a confident claim that “the data is clear.” A drug is mentio…

Stop the DIY Patent Search: The FTO Opinion Warning That Could Save You (and Your Company) From Willful Infringement
If you’ve ever heard “just do a quick patent search and you’ll be fine,” this is your reminder that quick is not the same as defensible…

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

The real price of a drug isn’t the invoice. It’s the total cost of ownership.
Pharma procurement teams have a familiar moment: the PO is approved, the contract is signed, and the “price” looks great—until the downstream costs start stacking up.
That’s …

Pharma doesn’t just invent drugs. It also buys time.
In the patent world, “extra time” can be worth billions—because when exclusivity ends, competition doesn’t arrive politely. It arrives fast, with generics and biosimilars that compress prices and mar…

Generic drugmakers don’t “wait their turn.” They litigate their way to the starting line.
For years, the public narrative around Hatch-Waxman has been simplified to a single idea: file an ANDA, challenge patents, and—if you win—launch sooner. But the…

Drug patent cliffs don’t just threaten revenue—they reshape procurement.
As exclusivity windows narrow, payers and pharmacy benefit managers don’t simply “wait for generics.” They actively redesign formularies, contracting terms, and substitution pat…